<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Adefovir: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Adefovir: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Adefovir: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11275" href="/d/html/11275.html" rel="external">see "Adefovir: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="86241" href="/d/html/86241.html" rel="external">see "Adefovir: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708606"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Severe acute exacerbations of hepatitis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti–hepatitis B therapy, including adefovir. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who discontinue anti–hepatitis B therapy. If appropriate, resumption of anti–hepatitis B therapy may be warranted.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In patients at risk of or having underlying renal dysfunction, long-term administration of adefovir may result in nephrotoxicity. Closely monitor renal function in these patients; they may require dose adjustment.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">HIV resistance:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">HIV resistance may emerge in chronic hepatitis B patients with unrecognized or untreated HIV infection treated with anti–hepatitis B therapies that may have activity against HIV (eg, adefovir).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lactic acidosis/severe hepatomegaly with steatosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F130623"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Hepsera [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865563"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AA-Adefovir;</li>
<li>Hepsera [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F130640"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihepadnaviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HBV)</li></ul></div>
<div class="block doa drugH1Div" id="F130625"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9203ca82-591f-48b9-85f3-5262945663e6">Chronic hepatitis B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis B:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Adefovir is not preferred in the management of chronic hepatitis B due to high rate of resistance with long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>); other guidelines do not recommend adefovir therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28427875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28427875'])">Ref</a></span>). Other antiviral agents with a high barrier to drug resistance are preferred (eg, tenofovir, entecavir) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329','lexi-content-ref-28427875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329','lexi-content-ref-28427875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg once daily; may be used as part of a combination regimen (concurrent use with tenofovir should be avoided) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment duration:</i> Treatment duration is variable and influenced by hepatitis B e antigen (HBeAg) status, duration of HBV suppression, and presence of cirrhosis/decompensation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Patients <i>without</i> cirrhosis:</p>
<p style="text-indent:-2em;margin-left:8em;">Hepatitis B e antigen positive (HBeAg-positive) immune-active chronic hepatitis: Treat until HBeAg seroconversion; after seroconversion, prolonged duration of therapy is often required in patients treated with nucleos(t)ide analogues. Optimal duration is unknown; however, consolidation therapy is generally a minimum of 12 months of persistently normal ALT and undetectable serum HBV DNA levels after HBeAg seroconversion if patient can be closely monitored. An alternative approach is to treat until hepatitis B surface antigen (HBsAg) loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329','lexi-content-ref-28427875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329','lexi-content-ref-28427875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">HBeAg-negative immune-active chronic hepatitis: Indefinite antiviral therapy is suggested unless there is competing rationale for discontinuation (risk/benefit decision); treatment discontinuation may be considered in patients with loss of HBsAg who have achieved long-term (≥3 years) virologic suppression; however, there is insufficient evidence to guide decisions in these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329','lexi-content-ref-28427875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329','lexi-content-ref-28427875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients <i>with</i> cirrhosis:</p>
<p style="text-indent:-2em;margin-left:8em;">HBeAg-positive immune-active chronic hepatitis: In patients who seroconvert on therapy, continue antiviral therapy indefinitely due to concerns with decompensation and death, unless there is a strong competing rationale for discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329','lexi-content-ref-28427875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329','lexi-content-ref-28427875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">HBeAg-negative immune-active chronic hepatitis: Treatment discontinuation is not recommended due to potential for decompensation and death (limited data) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329','lexi-content-ref-28427875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329','lexi-content-ref-28427875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Viral breakthrough: </i>Patients with confirmed viral breakthrough (HBV DNA ≥100 IU/mL with previously undetectable levels [&lt;10 IU/mL] or &gt;1 log increase in HBV DNA) should either be switched to an alternative antiviral monotherapy agent with a high genetic barrier to resistance or receive a second antiviral agent with a complementary resistance profile; consult current clinical practice guidelines for recommended agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992125"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 49 mL/minute: 10 mg every 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 29 mL/minute: 10 mg every 72 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute (nonhemodyalisis): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialyzable (~35%): 10 mg every 7 days (following dialysis)</p></div>
<div class="block doha drugH1Div" id="F50989339"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F130626"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F5657903"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="86241" href="/d/html/86241.html" rel="external">see "Adefovir: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9203ca82-591f-48b9-85f3-5262945663e6">Chronic hepatitis B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis B: Note:</b> Adefovir is not preferred due to high rate of resistance with long-term use; antivirals with a higher barrier to drug resistance are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329','lexi-content-ref-28427875','lexi-content-ref-28251116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329','lexi-content-ref-28427875','lexi-content-ref-28251116'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;7 years: Limited data available: Oral: 0.3 mg/kg/dose once daily; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18433023','lexi-content-ref-22466329','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18433023','lexi-content-ref-22466329','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 7 to &lt;12 years: Limited data available: Oral: 0.25 mg/kg/dose once daily; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18433023','lexi-content-ref-22466329','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18433023','lexi-content-ref-22466329','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Duration of therapy: </i>Optimal duration of treatment not established; oral antiviral therapy was continued for 1 to 4 years in trials; hepatitis B e antigen (HBeAg) seroconversion has been suggested as a therapeutic end point followed by an additional 12 months of consolidation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329','lexi-content-ref-22466329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329','lexi-content-ref-22466329'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51063377"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling (has not been studied); based on experience in adults, dosage adjustment should be considered.</p></div>
<div class="block dohp drugH1Div" id="F58819506"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: No dosage adjustments necessary.</p></div>
<div class="block adr drugH1Div" id="F130594"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (≥0.5 mg/dL: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Renal: Nephrotoxicity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypophosphatemia (Song 2020), lactic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Severe hepatomegaly with steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy, osteomalacia (Song 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Fanconi syndrome (Song 2020), nephrolithiasis (Lin 2017), proximal tubular nephropathy, renal failure syndrome (Xiang 2020)</p></div>
<div class="block coi drugH1Div" id="F130607"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to adefovir or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F130591"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Dosage adjustment is required in adult patients with renal dysfunction or in patients who develop renal dysfunction during therapy; no data available for use in children ≥12 years of age or adolescents with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tenofovir: Do not use concurrently with tenofovir (tenofovir disoproxil fumarate or tenofovir alafenamide) or any tenofovir-containing product.</p></div>
<div class="block foc drugH1Div" id="F130602"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as dipivoxil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hepsera: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block geq drugH1Div" id="F130587"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F130609"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Adefovir Dipivoxil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $37.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865564"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as dipivoxil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hepsera: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block adm drugH1Div" id="F130604"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to food.</p></div>
<div class="block admp drugH1Div" id="F52612185"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food.</p></div>
<div class="block use drugH1Div" id="F130603"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hepatitis B, chronic:</b> Treatment of chronic hepatitis B in patients ≥12 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. <b>Note:</b> Adefovir is not preferred in the management of chronic hepatitis B due to high rate of resistance with long-term use (AASLD [Terrault 2018]); other guidelines do not recommend adefovir therapy (EASL 2017). Other antiviral agents with a high barrier to drug resistance are preferred (eg, tenofovir, entecavir) (AASLD [Terrault 2018]; EASL 2017).</p></div>
<div class="block cyt drugH1Div" id="F13298688"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3; <b>Inhibits</b> MRP2</p></div>
<div class="block dri drugH1Div" id="F130596"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ataluren: May increase the serum concentration of Adefovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Adefovir may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Adefovir may diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Pivalate-Conjugated Medications may enhance the adverse/toxic effect of Valproate Products. Specifically, the risk for decreased carnitine concentrations is increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F130620"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food does not have a significant effect on adefovir absorption. Management: Administer without regard to meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F56621849"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Treatment for hepatitis B should be evaluated prior to pregnancy. Adefovir is not recommended for use in pregnant patients (AASLD [Terrault 2018]; EASL 2017).</p></div>
<div class="block pri drugH1Div" id="F130610"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Outcome data following maternal or paternal use of adefovir during pregnancy is limited (Funk 2021; Gao 2022; Gu 2014; Yang 2022; Yi 2012). Agents other than adefovir are recommended when hepatitis B treatment is needed in pregnant patients. Patients who become pregnant while taking adefovir should be switched to the preferred agent (AASLD [Terrault 2018]; EASL 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to adefovir is ongoing. Health care providers are encouraged to enroll patients exposed to adefovir during pregnancy in the Hepsera pregnancy registry (800-258-4263).</p></div>
<div class="block brc drugH1Div" id="F20519444"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if adefovir is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients requiring antivirals for hepatitis B may breastfeed if the infant received immunoprophylaxis at birth; however, recommendations are not specific to adefovir and other agents may be preferred (AASLD [Terrault 2018]; EASL 2017; SMFM 2016). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F130600"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">HIV status, CrCl (prior to initiation of therapy), HBV DNA and ALT (HBV DNA usually done every 3 months until undetectable and then every 3 to 6 months thereafter); HBeAg; anti-HBe (in patients who are HBeAg-positive to monitor for seroconversion); HBsAg; if at risk for renal impairment, CrCl, serum phosphate, urine glucose, and urine protein at baseline and at least annually; consider monitoring bone density in patients with risk factors for osteopenia or fracture history (prior to initiation and during therapy); lactic acid levels especially in patients with kidney dysfunction; following discontinuation, monitor for recurrent viremia, ALT flares, seroreversion, and clinical decompensation every 3 months for at least 1 year. Monitor for development of hepatocellular carcinoma as clinically indicated (ie, prolonged viremia, hepatitis C virus co-infection or cirrhosis) (AASLD [Terrault 2018]; EASL 2017; manufacturer’s labeling).</p></div>
<div class="block pha drugH1Div" id="F130590"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Acyclic nucleotide reverse transcriptase inhibitor (adenosine analog) which interferes with HBV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication.</p></div>
<div class="block phk drugH1Div" id="F130606"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Note:</b> Pharmacokinetic data reported in pediatric patients (12-18 years) similar to reported adult data.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 0.35 to 0.39 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ≤4% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Prodrug; rapidly converted to adefovir (active metabolite) in intestine </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 59% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 7.5 hours; prolonged in renal impairment </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Median: 1.75 hours (range: 0.58 to 4 hours)  </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (45% as active metabolite within 24 hours); Dialysis: ~35% of dose (10 mg) removed during 4 hours hemodialysis session </p></div>
<div class="block phksp drugH1Div" id="F51219894"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: C<sub>max</sub> and AUC increased in those with moderate or severe renal function impairment or with end-stage renal disease.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F130612"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Hepsera | Revervir</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-adefovir | Hepsera</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Infovir</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A gan ding | Dai ding | He wei li | Hepsera | Li fu zhi | Yi lai fen | You he ding | Yue bao</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Hepsera | Virofagon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Civirus | Dovocare | Fodavir | Hepsera</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adefovir dipivoxyl | Hepsera</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adesera | Adfovir | Adheb</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adecis | Adefor | Adefora | Adefosil | Adefovil | Adefovir | Adefovir b.r | Adepact | Adepam | Adepsera | Adeptin | Adesera | Adesil | Adesis | Adeva | Adevir | Afoliva | Aforiva | Afovil | Afovir | Apovir | Aprogen adefovir | Asevira | Austin adefovir | Baihepa | Boryung adefovir | Everhepa | Hepasera | Hepavir | Hepcetovi | Hepcevir | Hepcure | Heppure | Hepsa | Hepsava | Hepsedefo | Hepsedepo | Hepsel | Hepsera | Hepseron | Hepserusa | Hepses | Hepsevir | Hepsk | Hepssel | Heptec | Hepxa | Hevir | Inist adefovir | Liversera | Sunsera | Uniliver | Wonderhepa</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Adesera</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adeday | Adefo | Hepbi | Hepovir | Hepsera | Medfir | Zurax</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Hepsera</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Adefovir dipivoxil tablet [prescribing information]. Bensalem, PA: Sigmapharm Laboratories, LLC; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28427875">
<a name="28427875"></a>European Association for the Study of the Liver (EASL). European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. <i>J Hepatol</i>. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/28427875/pubmed" id="28427875" target="_blank">28427875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32805200">
<a name="32805200"></a>Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. <i>Lancet Infect Dis</i>. 2021;21(1):70-84. doi:10.1016/S1473-3099(20)30586-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/32805200/pubmed" id="32805200" target="_blank">32805200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32019360">
<a name="32019360"></a>Gao X, Duan X, Cai H, et al. Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy.<i> J Matern Fetal Neonatal Med</i>. 2022;35(3):476-480. doi:10.1080/14767058.2020.1723540<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/32019360/pubmed" id="32019360" target="_blank">32019360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25174874">
<a name="25174874"></a>Gu Y, Ru T, Zhou YH, Hu Y. Adefovir as a possible teratogen: evidence from paternal exposure. <i>Dig Liver Dis</i>. 2014;46(12):1134-1135. doi:10.1016/j.dld.2014.08.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/25174874/pubmed" id="25174874" target="_blank">25174874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12606734">
<a name="12606734"></a>Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B [published correction appears in:<i> N Engl J Med</i>. 2003;348(12):1192]. <i>N Engl J Med</i>. 2003;348(9):800-807.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/12606734/pubmed" id="12606734" target="_blank">12606734</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hepsera (adefovir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2012.</div>
</li>
<li>
<div class="reference">
                  Hepsera (adefovir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18433023">
<a name="18433023"></a>Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to &lt;18 years) with chronic hepatitis B. <i>Hepatology</i>. 2008;47(6):1863-1871. doi: 10.1002/hep.22250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/18433023/pubmed" id="18433023" target="_blank">18433023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22466329">
<a name="22466329"></a>Jonas MM, Kelly D, Pollack H, et al. Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. <i>Pediatr Infect Dis J</i>. 2012;31(6):578-582. doi: 10.1097/INF.0b013e318255ffe7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/22466329/pubmed" id="22466329" target="_blank">22466329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28251116">
<a name="28251116"></a>Komatsu H, Inui A, Fujisawa T. Pediatric hepatitis B treatment. <i>Ann Transl Med</i>. 2017;5(3):37. doi:10.21037/atm.2016.11.52<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/28251116/pubmed" id="28251116" target="_blank">28251116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28851305">
<a name="28851305"></a>Lin J, Zhuo Y, Zhang D. Nephrolithiasis and Osteomalacia associated with adefovir-induced Fanconi syndrome in a patient with hepatitis B. <i>BMC Nephrol</i>. 2017;18(1):275. doi:10.1186/s12882-017-0693-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/28851305/pubmed" id="28851305" target="_blank">28851305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12606735">
<a name="12606735"></a>Marcellin P, Chang TT, Lim SG, et al; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. <i>N Engl J Me</i>d. 2003;348(9):808-816. doi: 10.1056/NEJMoa020681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/12606735/pubmed" id="12606735" target="_blank">12606735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26454123">
<a name="26454123"></a>Society for Maternal-Fetal Medicine (SMFM), Dionne-Odom J, Tita AT, Silverman NS. #38: hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. <i>Am J Obstet Gynecol.</i> 2016;214(1):6-14. doi:10.1016/j.ajog.2015.09.100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/26454123/pubmed" id="26454123" target="_blank">26454123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33100076">
<a name="33100076"></a>Song K, Yan Q, Yang Y, et al. Fanconi syndrome induced by adefovir dipivoxil: a case report and clinical review. <i>J Int Med Res</i>. 2020;48(10):300060520954713. doi:10.1177/0300060520954713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/33100076/pubmed" id="33100076" target="_blank">33100076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29405329">
<a name="29405329"></a>Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i>. 2018;67(4):1560-1599. doi:10.1002/hep.29800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/29405329/pubmed" id="29405329" target="_blank">29405329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26566064">
<a name="26566064"></a>Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. <i>Hepatology</i>. 2016;63(1):261-283. doi: 10.1002/hep.28156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/26566064/pubmed" id="26566064" target="_blank">26566064</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new</a>. Updated September 14, 2023. Accessed October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35046808">
<a name="35046808"></a>Yang R, Yin N, Zhao Y, et al. Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA adverse event reporting system. <i>Front Pharmacol</i>. 2022;12:772768. doi:10.3389/fphar.2021.772768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/35046808/pubmed" id="35046808" target="_blank">35046808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32503675">
<a name="32503675"></a>Xiang Q, Liu Z, Yu Y, et al. Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose adefovir dipivoxil: a case report. <i>BMC Pharmacol Toxicol</i>. 2020;21(1):43. doi:10.1186/s40360-020-00421-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/32503675/pubmed" id="32503675" target="_blank">32503675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23236240">
<a name="23236240"></a>Yi W, Liu M, Cai HD. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. <i>World J Gastroenterol</i>. 2012;18(45):6645-6650. doi: 10.3748/wjg.v18.i45.6645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adefovir-drug-information/abstract-text/23236240/pubmed" id="23236240" target="_blank">23236240</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8690 Version 222.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
